Duke University

University System of Maryland

Kevin J Wiehe

Barton F Haynes

Hua-Xin Liao

M Anthony Moody

Mattia Bonsignori

Gilad Adi Ofek

LaTonya Williams

S Munir Alam

Kevin O Saunders

David C Montefiori

Celia C Labranche

Rory Henderson

The technology is directed to HIV envelopes which comprise sequence modifications wherein these modifications prevent CD4-induced transitions of the HIV envelope. Specifically, the disclosure provides recombinant HIV-1 Env proteins comprising mutations, wherein the envelope is a protomer, and wherein three protomers form a trimer stabilized by the presence of the mutations. Provided also are compositions comprising envelopes of the technology, and methods of use.

HIV-1 envelope stabilizing mutations

The invention is directed to HIV-1 neutralizing antibodies and methods for their uses.

HIV-1 neutralizing antibodies and uses thereof

The invention is directed to immunogens and methods for inducing immune responses, comprising methods for germline B cell stimulation and maturation by reverse engineering of HIV-1 envelopes.

Compositions comprising modified HIV envelopes

The invention is directed to methods to identify improbable mutations in the heavy or light chain variable domain of an antibody, methods to identify antigens which bind to antibodies comprising such improbable mutations, and methods of using such antigens to induce immune responses.

Methods to identify immunogens by targeting improbable mutations

Growing community of inventors

Durham, NC, United States of America

Kevin J Wiehe